NASDAQ:HALO

Halozyme Therapeutics Earnings Date, Estimates & History

$40.91

+0.50 (+1.24 %)

(As of 03/5/2021 12:00 AM ET)

Add

Compare

Today's Range

$38.81

Now: $40.91▼

$41.03

50-Day Range

$40.41

MA: $48.07▼

$51.45

52-Week Range

$12.71

Now: $40.91▼

$56.40

Volume2.10 million shs

Average Volume1.55 million shs

Market Capitalization$5.53 billion

P/E Ratio255.69

Dividend YieldN/A

Beta1.77

Halozyme Therapeutics (NASDAQ:HALO) Earnings Information

Halozyme Therapeutics last announced its quarterly earnings results on February 23rd, 2021. The biopharmaceutical company reported $0.50 earnings per share for the quarter, missing the consensus estimate of $0.56 by $0.06. The business had revenue of $121.70 million for the quarter, compared to analyst estimates of $120.75 million. Its revenue was up 126.6% on a year-over-year basis. Halozyme Therapeutics has generated ($0.50) earnings per share over the last year and currently has a price-to-earnings ratio of 255.7. Halozyme Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 10th, 2021 based off prior year's report dates.

Halozyme Therapeutics Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Halozyme Therapeutics (NASDAQ:HALO) Earnings Estimates

2021 EPS Consensus Estimate: $1.52
2022 EPS Consensus Estimate: $2.76

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2021	3	$0.23	$0.34	$0.29
Q2 2021	3	$0.26	$0.40	$0.33
Q3 2021	3	$0.32	$0.52	$0.41
Q4 2021	2	$0.47	$0.50	$0.49
Q1 2022	1	$0.58	$0.58	$0.58
Q2 2022	1	$0.64	$0.64	$0.64
Q3 2022	1	$0.71	$0.71	$0.71
Q4 2022	1	$0.83	$0.83	$0.83

Halozyme Therapeutics (NASDAQ HALO) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Reported EPS	GAAP EPS	Revenue Estimate	Actual Revenue	Conference Call
5/10/2021 (Estimated)
2/23/2021	12/31/2020	$0.56	$0.50	$0.50	$120.75 million	$121.70 million	Transcript
11/2/2020	9/30/2020	$0.20	$0.25	$0.25	$59.35 million	$65.30 million	Transcript
8/10/2020	6/30/2020	$0.25	$0.19	$0.19	$65.81 million	$55.22 million	Transcript
5/11/2020	3/31/2020	($0.02)	($0.04)	($0.04)	$42.96 million	$25.30 million	Transcript
2/24/2020	Q4 2019	($0.18)	($0.24)	($0.24)	$55.69 million	$53.70 million	Transcript
11/12/2019	9/30/2019	($0.12)	($0.1712)	($0.17)	$54.96 million	$46.20 million	Transcript
8/6/2019	Q2 2019	($0.17)	($0.1006)	($0.10)	$42.94 million	$39.10 million	Listen
5/7/2019	3/31/2019	$0.01	$0.01	$0.01	$67.80 million	$56.95 million	N/A
2/21/2019	12/31/2018	($0.03)	($0.01)	($0.01)	$59.77 million	$60.23 million	Listen
11/6/2018	9/30/2018	($0.23)	($0.19)	($0.19)	$30.42 million	$25.60 million	Listen

8/7/2018	Q2 2018	($0.22)	($0.1590)	($0.16)	$31.49 million	$35.20 million	N/A
5/10/2018	Q1 2018	($0.22)	($0.19)	($0.19)	$31.84 million	$30.90 million	N/A
2/20/2018	Q4 2017	$0.58	$0.85	$0.85	$173.11 million	$189.60 million	Transcript
11/7/2017	Q3 2017	$0.06	$0.0190	$0.02	$58.95 million	$63.73 million	N/A
8/8/2017	Q2 2017	($0.25)	($0.23)	($0.23)	$31.76 million	$33.80 million	Listen
5/9/2017	Q1 2017	($0.25)	($0.26)	($0.26)	$30.79 million	$29.60 million	Listen
2/28/2017	Q416	($0.30)	($0.21)	($0.21)	$37.94 million	$39.00 million	Listen
11/7/2016	Q316	($0.27)	($0.23)	($0.23)	$34.43 million	$31.90 million	Listen
8/9/2016	Q216	($0.27)	($0.21)	($0.21)	$29.94 million	$33.30 million	N/A
5/9/2016	Q116	($0.20)	($0.16)	($0.16)	$29.65 million	$42.50 million	N/A
2/29/2016	Q415	($0.08)	$0.03	$0.03	$37.06 million	$52.20 million	Listen
11/9/2015	Q315	($0.16)	($0.19)	($0.19)	$24.01 million	$20.80 million	N/A
8/10/2015	Q215	($0.09)	$0.02	$0.02	$24.84 million	$43.40 million	Listen
5/11/2015	Q115	($0.13)	($0.12)	($0.12)	$19.40 million	$18.70 million	Listen
3/2/2015	Q414	($0.07)	($0.04)	($0.04)	$25.60 million	$30.38 million	N/A
11/10/2014	Q314	($0.14)	($0.16)	($0.16)	$16.50 million	$14.60 million	N/A
8/11/2014	Q214	($0.18)	($0.13)	($0.13)	$13.71 million	$18.40 million	N/A
5/12/2014	Q114	($0.14)	($0.22)	($0.22)	$13.37 million	$12.00 million	N/A
2/27/2014	Q4 2013	($0.17)	($0.19)	($0.19)	$21.80 million	$12.50 million	Listen
11/8/2013	Q3 2013	($0.14)	($0.17)	($0.17)	$14.62 million	$16.00 million	N/A
8/7/2013	Q2 2013	($0.14)	($0.20)	($0.20)	$11.29 million	$14.50 million	Transcript
5/8/2013	Q1 2013	($0.15)	($0.17)	($0.17)	$7.05 million	$11.83 million	Listen
2/25/2013	Q4 2012	($0.16)	($0.04)		$7.32 million	$21.80 million	Listen
11/8/2012	Q312	($0.13)	($0.18)		$6.09 million	$5.33 million	Transcript
8/6/2012		($0.15)	($0.13)				N/A
5/7/2012		($0.11)	$0.14				N/A
3/9/2012		($0.16)	($0.18)				N/A
11/7/2011		($0.03)	$0.05				Transcript
8/5/2011	Q2 2011	($0.13)	$0.03	$0.03			N/A
5/6/2011	Q1 2011	($0.13)	($0.10)	($0.10)			N/A
3/11/2011	Q4 2010	($0.12)	($0.17)	($0.17)			N/A
11/5/2010	Q3 2010	($0.13)	($0.13)	($0.13)			N/A
8/6/2010	Q2 2010	($0.14)	($0.13)	($0.13)			N/A
5/7/2010	Q1 2010	($0.16)	($0.13)	($0.13)			N/A
3/12/2010	Q4 2009	($0.16)	($0.14)	($0.14)			N/A
11/6/2009	Q3 2009	($0.18)	($0.16)	($0.16)			N/A
8/7/2009	Q2 2009	($0.16)	($0.21)	($0.21)			N/A
5/8/2009	Q1 2009	($0.15)	($0.18)	($0.18)			N/A
3/13/2009	Q4 2008	($0.13)	($0.21)	($0.21)			N/A
11/6/2008	Q3 2008	($0.14)	($0.14)	($0.14)			N/A
8/8/2008	Q2 2008	($0.13)	($0.14)	($0.14)			N/A
5/8/2008	Q1 2008	($0.12)	($0.13)	($0.13)			N/A
3/13/2008	Q4 2007	($0.09)	($0.11)	($0.11)			N/A

(Earnings results data provided by Zacks Investment Research)

This page was last updated on 3/7/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Halozyme Therapeutics Earnings Date, Estimates & History

Adding

Adding

Adding Halozyme Therapeutics, Inc.

Earnings

Halozyme Therapeutics (NASDAQ:HALO) Earnings Information

Halozyme Therapeutics Earnings Estimates and Actuals by Quarter

Halozyme Therapeutics (NASDAQ:HALO) Earnings Estimates

Halozyme Therapeutics (NASDAQ HALO) Earnings History by Quarter

30 Days of MarketBeat All Access for $1.00

Premium Research Tools

Market Data and Calendars

Investing Education and Resources